Literature DB >> 16725386

A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum.

Robert A Parise1, Julianne L Holleran, Jan H Beumer, Suresh Ramalingam, Merrill J Egorin.   

Abstract

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is undergoing evaluation as an antineoplastic agent. We developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for quantitating vorinostat and its major metabolites, vorinostat glucuronide and 4-anilino-4-oxobutanoic acid, in human serum. The assay uses: deuterated internal standards; acetonitrile protein precipitation; a BDS Hypersil C18 (3 microm, 100 mm x 3 mm) column; a gradient mobile phase of 0.5% acetic acid in acetonitrile and water; and electrospray positive-mode ionization with selected reaction monitoring (SRM) detection. The lower limit of quantitation was 3.0 ng/ml for each analyte. The assay is being employed in at least 12 clinical studies of vorinostat-containing regimens.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16725386     DOI： 10.1016/j.jchromb.2006.04.044

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN： 1570-0232            Impact factor:   3.205


  35 in total

1.  A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.

Authors:  Tapan M Kadia; Hui Yang; Alessandra Ferrajoli; Sirisha Maddipotti; Claudia Schroeder; Timothy L Madden; Julianne L Holleran; Merrill J Egorin; Farhad Ravandi; Deborah A Thomas; Willie Newsome; Blanca Sanchez-Gonzalez; James A Zwiebel; Igor Espinoza-Delgado; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal:  Br J Haematol       Date:  2010-04-29       Impact factor: 6.998

Review 2.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

3.  A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.

Authors:  William R Schelman; Anne M Traynor; Kyle D Holen; Jill M Kolesar; Steven Attia; Tien Hoang; Jens Eickhoff; Zhisheng Jiang; Dona Alberti; Rebecca Marnocha; Joel M Reid; Matthew M Ames; Renee M McGovern; Igor Espinoza-Delgado; John J Wright; George Wilding; Howard H Bailey
Journal:  Invest New Drugs       Date:  2013-10-10       Impact factor: 3.850

4.  A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.

Authors:  Dustin A Deming; Jacob Ninan; Howard H Bailey; Jill M Kolesar; Jens Eickhoff; Joel M Reid; Matthew M Ames; Renee M McGovern; Dona Alberti; Rebecca Marnocha; Igor Espinoza-Delgado; John Wright; George Wilding; William R Schelman
Journal:  Invest New Drugs       Date:  2013-10-10       Impact factor: 3.850

5.  Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.

Authors:  Jesse J McClure; Cheng Zhang; Elizabeth S Inks; Yuri K Peterson; Jiaying Li; C James Chou
Journal:  J Med Chem       Date:  2016-10-26       Impact factor: 7.446

Review 6.  Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.

Authors:  Paul Helquist; Frederick R Maxfield; Norbert L Wiech; Olaf Wiest
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

7.  Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer.

Authors:  Vered Stearns; Lisa K Jacobs; Maryjo Fackler; Theodore N Tsangaris; Michelle A Rudek; Michaela Higgins; Julie Lange; Zandra Cheng; Shannon A Slater; Stacie C Jeter; Penny Powers; Susanne Briest; Calvin Chao; Carl Yoshizawa; Elizabeth Sugar; Igor Espinoza-Delgado; Saraswati Sukumar; Edward Gabrielson; Nancy E Davidson
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

8.  Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.

Authors:  Devalingam Mahalingam; Monica Mita; John Sarantopoulos; Leslie Wood; Ravi K Amaravadi; Lisa E Davis; Alain C Mita; Tyler J Curiel; Claudia M Espitia; Steffan T Nawrocki; Francis J Giles; Jennifer S Carew
Journal:  Autophagy       Date:  2014-05-20       Impact factor: 16.016

9.  A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).

Authors:  Jodi A Muscal; Patrick A Thompson; Terzah M Horton; Ashish M Ingle; Charlotte H Ahern; Renee M McGovern; Joel M Reid; Matthew M Ames; Igor Espinoza-Delgado; Brenda J Weigel; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2012-08-09       Impact factor: 3.167

10.  Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

Authors:  P N Munster; D Marchion; S Thomas; M Egorin; S Minton; G Springett; J-H Lee; G Simon; A Chiappori; D Sullivan; A Daud
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.